Test Catalog

Test ID: CD30    
CD30 Immunostain, Technical Component Only

Useful For Suggests clinical disorders or settings where the test may be helpful

Identification of CD30 expression in a variety of neoplasms

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

CD30 is a member of the tumor necrosis factor receptor (TNF-R) superfamily. Expression of CD30 can also be seen in embryonal carcinomas, malignant melanomas, mesenchymal tumors, and activated T and B lymphocytes and plasma cells. Reed-Sternberg cells of classic Hodgkin lymphoma, as well as the neoplastic cells of anaplastic large cell lymphoma, express CD30.

Interpretation Provides information to assist in interpretation of the test results

This test does not include pathologist interpretation; only technical performance of the stain. If an interpretation is required order PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case.


The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request. Contact 855-516-8404.


Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen-dependent. Best practice is for paraffin sections to be cut within 6 weeks.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Goyal A, Patel S, Goyal K, Morgan EA, Foreman RK: Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. J Cutan Pathol. 2019:Nov;46(11):823-829. doi: 10.1111/cup.13545

2. Bossard C, Dobay MP, Parrens M, et al: Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014:Nov 6;124(19):2983-2986. doi: 10.1182/blood-2014-07-584953

3. Sabattini E, Pizzi M, Tabanelli V, et al: CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81-e82